WCN26-6827 EFFICACY AND SAFETY OF BUDESONIDE DELAYED-RELEASE CAPSULES COMBINED WITH AMBRISENTAN FOR IgA NEPHROPATHY

Read full text Summarise with VIRAT
Authors: Yanrong Yang, Ran Zhang, Xiaoxuan Zhao, Shuxin Yu, Weixia Sun
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Objective: IgA nephropathy (IgAN) is a mesangioproliferative glomerulonephritis characterized by glomerular mesangial deposition of galactose-deficient IgA1 (Gd-IgA1) immune complexes, and currently lacks specific treatment options. Budesonide delayed-release capsules target the distal ileal mucosal lymphoid tissue, modulating immune responses and reducing Gd-IgA1 production. Ambrisentan, as a highly selective endothelin receptor antagonist, improves glomerular endothelial function and reduces proteinuria.

Fields of Study & Subjects

Renal Diseases and Glomerulopathies Chronic Kidney Disease and Diabetes Vasculitis and related conditions

Publication details

Journal / source
Kidney International Reports
Volume
11
Issue
4
Pages
104637–104637
Publication date
25 March 2026
Language
EN